[{"orgOrder":0,"company":"GUERBET","sponsor":"Bracco","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Gadopiclenol","moa":"gadolinium derivatives (principally for diagnostic use)","graph1":"Neurology","graph2":"Phase III","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GUERBET \/ Bracco","highestDevelopmentStatusID":"10","companyTruncated":"GUERBET \/ Bracco"},{"orgOrder":0,"company":"GUERBET","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Gadopiclenol","moa":"gadolinium derivatives (principally for diagnostic use)","graph1":"Undisclosed","graph2":"Phase III","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"GUERBET \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GUERBET \/ Undisclosed"},{"orgOrder":0,"company":"GUERBET","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Gadopiclenol","moa":"gadolinium derivatives (principally for diagnostic use)","graph1":"Oncology","graph2":"Phase III","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GUERBET \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GUERBET \/ Undisclosed"},{"orgOrder":0,"company":"GUERBET","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Gadopiclenol","moa":"gadolinium derivatives (principally for diagnostic use)","graph1":"Neurology","graph2":"Phase II","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GUERBET \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GUERBET \/ Undisclosed"},{"orgOrder":0,"company":"University of California, San Diego","sponsor":"Bracco","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Gadopiclenol","moa":"gadolinium derivatives (principally for diagnostic use)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"University of California, San Diego","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Diego \/ Bracco","highestDevelopmentStatusID":"10","companyTruncated":"University of California, San Diego \/ Bracco"},{"orgOrder":0,"company":"UConn Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Gadopiclenol","moa":"gadolinium derivatives (principally for diagnostic use)","graph1":"Undisclosed","graph2":"Phase IV","graph3":"UConn Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UConn Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"UConn Health \/ Undisclosed"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"GUERBET","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Gadopiclenol","moa":"gadolinium derivatives (principally for diagnostic use)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johns Hopkins University \/ GUERBET","highestDevelopmentStatusID":"11","companyTruncated":"Johns Hopkins University \/ GUERBET"},{"orgOrder":0,"company":"University of Massachusetts, Worcester","sponsor":"GUERBET","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Gadopiclenol","moa":"gadolinium derivatives (principally for diagnostic use)","graph1":"Oncology","graph2":"Phase IV","graph3":"University of Massachusetts, Worcester","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Massachusetts, Worcester \/ GUERBET","highestDevelopmentStatusID":"11","companyTruncated":"University of Massachusetts, Worcester \/ GUERBET"}]

Find Clinical Drug Pipeline Developments & Deals for Gadolinium-based Magnetic Resonance Contrast Agent P03277

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          UConn Health

                          Country arrow
                          PREP
                          Not Confirmed

                          UConn Health

                          Country arrow
                          PREP
                          Not Confirmed

                          Details : Gadopiclenol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Contrast Enhanced Imaging.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 26, 2025

                          Lead Product(s) : Gadopiclenol

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          University of California, San Diego

                          Country arrow
                          PREP
                          Not Confirmed

                          University of California, San Diego

                          Country arrow
                          PREP
                          Not Confirmed

                          Details : Gadopiclenol is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Heart Defects, Congenital.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 09, 2024

                          Lead Product(s) : Gadopiclenol

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Bracco

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          University of Massachusetts, Worcester

                          Country arrow
                          PREP
                          Not Confirmed

                          University of Massachusetts, Worcester

                          Country arrow
                          PREP
                          Not Confirmed

                          Details : Gadopiclenol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Prostatic Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 26, 2024

                          Lead Product(s) : Gadopiclenol

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase IV

                          Sponsor : GUERBET

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Elucirem (Gadopiclenol) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Brain Neoplasms.

                          Product Name : Elucirem

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 28, 2023

                          Lead Product(s) : Gadopiclenol

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Gadopiclenol is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Brain Lesions.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 24, 2023

                          Lead Product(s) : Gadopiclenol

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Bracco

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Johns Hopkins University

                          Country arrow
                          PREP
                          Not Confirmed

                          Johns Hopkins University

                          Country arrow
                          PREP
                          Not Confirmed

                          Details : Elucirem (Gadopiclenol) is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Myocardial Fibrosis.

                          Product Name : Elucirem

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 20, 2023

                          Lead Product(s) : Gadopiclenol

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase IV

                          Sponsor : GUERBET

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Gadopiclenol is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Central Nervous System Diseases.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 21, 2022

                          Lead Product(s) : Gadopiclenol

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Gadopiclenol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 28, 2021

                          Lead Product(s) : Gadopiclenol

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Gadopiclenol is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Brain Lesions.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 24, 2019

                          Lead Product(s) : Gadopiclenol

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Gadopiclenol is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 14, 2019

                          Lead Product(s) : Gadopiclenol

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank